a first-in-class mitochondria-targeted therapeutic in development for individuals with Barth syndrome. The new PDUFA target action date is April 29, 2025. Stealth BioTherapeutics Logo (PRNewsFoto ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback